When was Avidity Biosciences founded?

Avidity Biosciences was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Avidity Biosciences located?

Avidity Biosciences is headquartered in San Diego, United States.

How many employees does Avidity Biosciences have?

As of Jul 31, 2026, the latest employee count at Avidity Biosciences is 432.

Is Avidity Biosciences a funded company?

Avidity Biosciences is a funded company, having raised a total of $143M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 14, 2014.

How much is Avidity Biosciences worth?

The last known valuation of Avidity Biosciences was $***** as of Jun 11, 2020.

When was the latest funding round of Avidity Biosciences?

Avidity Biosciences' latest funding was a $***** Post IPO round on Mar 04, 2024, with participation from 0 investor.

What is the annual revenue of Avidity Biosciences?

Annual revenue of Avidity Biosciences is between $10M and $50M as on Dec 31, 2025

Where does Avidity Biosciences rank among its competitors?

Avidity Biosciences ranks 2nd amongst 79 active competitors, of which 32 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Avidity Biosciences?

Avidity Biosciences' top competitors include Alnylam, Sirnaomics and Alchemab. Among them, Alchemab secured the most recent funding round in July, 2026.

Avidity Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Avidity Biosciences is an acquired company based in San Diego (United States), founded in 2012. It operates as a RNA therapeutics innovator targeting muscle and other diseases with AOC platform. Avidity Biosciences has raised $143M in funding from investors like Lilly, Takeda Ventures and RTW Investments, with last known valuation of $*****. The company has 79 active competitors, including 32 funded and 24 that have exited. Its top competitors include companies like Alnylam, Sirnaomics and Alchemab.

Company Details

RNA therapeutics innovator targeting muscle and other diseases with AOC platform. The company is dedicated to improving lives through targeted RNA therapeutics, utilizing its Antibody Oligonucleotide Conjugates (AOC™) platform. The focus is on addressing the root causes of diseases, particularly in muscle disease. The innovative pipeline is designed to expand into various cells and tissues, addressing unmet patient needs across a wide range of therapeutic areas. The AOC platform combines the specificity of monoclonal antibodies with the precision of oligonucleotides to deliver treatments to previously inaccessible tissues and cells, effectively targeting the underlying genetic drivers of diseases. The company is advancing pipeline programs to offer treatment options for patients and their families. The company is a biotechnology company focused on research and development.

Website: www.aviditybiosciences.com/
Email ID: *****@aviditybio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

San Diego, United States

Stage

Acquired

Total Funding

$143M in 7 rounds

Latest Funding Round

Post IPO, Mar 04, 2024, $*****

Last Known Valuation

$***** as on Jun 11, 2020

Investors

Lilly & 21 more

Ranked

2^nd among 79 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

432 as on Jul 31, 2026

Similar Companies

Alnylam & 101 more

Exit Details

Acquired by Novartis (Oct 27, 2025)

View Avidity Biosciences' full profile

Avidity Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVIDITY BIOSCIENCES LLC CIN: 401-7900 , Belgium, Active	Nov 12, 2012	-	253 (As on Feb 29, 2024)	-
Avidity Biosciences, Inc. CIN: 1599901 , United States, Active	Nov 12, 2012	$10M - $50M (As on Dec 31, 2025)	-	-

Avidity Biosciences got acquired by Novartis on Oct 27, 2025 at an acquisition amount of $*****.

Click here to take a look at Avidity Biosciences's acquisition in detail

Avidity Biosciences has raised a total funding of $143M over 7 rounds. Its first funding round was on Feb 14, 2014. Avidity Biosciences has 22 institutional investors.

Here is the list of recent funding rounds of Avidity Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2024	6899538	Post IPO	2767085	1079448	2954379	3972482
Nov 13, 2019	6229167	Series C	6629707	7563222	9580404	ST PHARM & 11 more
Apr 22, 2019	7842047	Series B	2144675	6181873	Lilly	5138996

Access funding benchmarks and valuations. Sign up today!

View details of Avidity Biosciences's funding rounds and investors

Avidity Biosciences' employee count trend

Avidity Biosciences has 432 employees as of Jul 26. Here is Avidity Biosciences's employee count trend over the years:

Employee count trend for Avidity Biosciences

Uncover Avidity Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avidity Biosciences include Alnylam, Sirnaomics and Alchemab. Here is the list of Top 10 competitors of Avidity Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	Boxer Capital, RTW Investments & 20 others	66/100
3rd	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
4th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100
5th	City Therapeutics 2006, Cambridge (United States), Series B	Developer of gene therapies for multiple diseases	$234M	Viking Global Investors, Sofinnova Investments ... & 9 others	63/100
6th	Arrowhead Pharmaceuticals 1989, Pasadena (United States), Acquired	Developer of therapeutics to treat multiple diseases	$60M	Colt Ventures, Amgen Business Development ... & 8 others	62/100
7th	Juvena Therapeutics 2017, San Mateo (United States), Series B	Company developing protein based therapies for sarcopenia and muscle regeneration	$86.3M	Mubadala, Horizons Ventures & 23 others	62/100
8th	OliX Pharmaceuticals 2010, Suwon-si (South Korea), Public	Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.	-	IMM Investment, Kolon Investments & 16 others	61/100
9th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	Domain Associates, RA Capital Management ... & 18 others	60/100
10th	Souzhou Ribo Life Science 2007, Suzhou (China), Public	Developer of nucleic acid drugs based on RNA interference (RNAi) technology	$201M	Panlin Capital, Legend Capital & 13 others	60/100